Triple
T2371004
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Rituxan |
E46089
|
entity |
| Predicate | hasINN |
P23160
|
FINISHED |
| Object | rituximab |
E46089
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: rituximab | Statement: [Rituxan, hasINN, rituximab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: rituximab Context triple: [Rituxan, hasINN, rituximab]
-
A.
Rituxan
chosen
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a88a145268819083e2736cb835c696 |
completed | March 4, 2026, 7:37 p.m. |
| NER | Named-entity recognition | batch_69abc76f5aec8190867d621e6849258c |
completed | March 7, 2026, 6:36 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69aea8a2b1448190b19179cf379993ee |
completed | March 9, 2026, 11:01 a.m. |
Created at: March 4, 2026, 7:56 p.m.